A Phase 3 interventional study of Diclofenac sodium gel 1% and Voltaren® Gel (Diclofenac Sodium Topical Gel) 1% in Osteoarthritis, Knee, sponsored by Mylan Pharmaceuticals Private Limited. Completed at 32 sites in India. Open to participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2022-03-03.
Sponsored by Mylan Pharmaceuticals Private Limited (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Osteoarthritis, Knee with a site in India — 1 open to participants now, 1 under way, none of them phase 3. Osteoarthritis, Knee · India.
Among the 24 studies in Osteoarthritis, Knee with a site in India, this one is the 2nd largest by enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2017, is one of 2 in phase 3, and was the 7th registered.
3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.
Browse Osteoarthritis, Knee studies →1 of the 24 studies in Osteoarthritis, Knee with a site in India is open now. Recruiting first, the newest first:
All India Institute of Medical Sciences, Jodhpur · Sites in India
Ages 30–65
A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →
Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 35 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 2 · Phase 4 4
First in 2007; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,220 is above the median of 68 across 2,717 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 104 across the 22 interventional studies, 578 across the 2 observational. Of the 21 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 24 have an industry lead sponsor. The 10 most frequent:
This study is registered under Mylan Pharmaceuticals Private Limited, one of the names counted as Viatris Inc.. Under that name alone:
This is the only study on the registry with Mylan Pharmaceuticals Private Limited as lead sponsor.
Viatris Inc. has 7 studies filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 24 studies in Osteoarthritis, Knee with a site in India, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This randomized, double-blind, three-arm, placebo controlled, bioequivalence study with clinical endpoint has been designed to establish clinical equivalence and safety of Mylan's diclofenac gel in the symptomatic treatment of osteoarthritis of knee compared to Voltaren® gel and to establish superiority in efficacy of both compared to a placebo (vehicle) gel.
Male or non-pregnant female aged ≥ 35 years with a clinical diagnosis of osteoarthritis of the knee according to the American College of Rheumatology (ACR) criteria
Total study duration for the clinical part will be around 56 days that includes screening period of 28 days and treatment period of 4 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diclofenac Sodium Gel, 1%
Drug: Diclofenac sodium gel 1%
Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%
Drug: Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%
Placebo gel
Drug: Placebo gel
Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
Vehicle Gel 4 gm, 4 times a day for 4 weeks
Mean Change in the Total WOMAC Pain Subscale Score
Mean change in the total WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain subscale score for the target knee was compared to determine the clinical equivalence of Test Drug (Diclofenac sodium gel of 1% of Mylan Inc.) with the Reference Listed Drug (RLD) (Voltaren® Gel 1% of Novartis Consumer Health, Inc.) Measure Description: Western Ontario and McMaster Universities Osteoarthritis Index WOMAC pain subscale score (pain score = min 0 to max 20), was determined by the sum of subject's responses to five questions (S1-S5) using a 5-point Likert scale (i.e., 'none'=0; 'mild'=1, 'moderate'=2; 'severe'=3; 'extreme'=4). Higher values represent worse outcome. 'How much pain do you have' when 'Walking on a flat surface' (S1), 'Going up or down stairs' (S2), 'at night while in bed' (S3), 'Sitting or lying' (S4), 'Standing upright' (S5)\]. The timepoints considered for the primary outcomes include baseline and week 4.
Time frame: From baseline to week 4
Change From Baseline in WOMAC Pain Subscale Score
Mean change in the total WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain subscale score for the target knee was compared to determine the superiority of the Test Drug and Reference Listed Drug (RLD) over placebo. Measure Description: Western Ontario and McMaster Universities Osteoarthritis Index WOMAC pain subscale score (pain score = min 0 to max 20), was determined by the sum of subject's responses to five questions (S1-S5) using a 5-point Likert scale (i.e., 'none'=0; 'mild'=1, 'moderate'=2; 'severe'=3; 'extreme'=4). Higher values represent worse outcome. 'How much pain do you have' when 'Walking on a flat surface' (S1), 'Going up or down stairs' (S2), 'at night while in bed' (S3), 'Sitting or lying' (S4), 'Standing upright' (S5)\]. The timepoints considered for the primary outcomes include baseline and week 4.
Time frame: 4 weeks
| Milestone | Diclofenac Sodium Gel | Voltaren® Gel | Placebo Gel |
|---|---|---|---|
| Started | 406 | 409 | 405 |
| Completed | 388 | 389 | 389 |
| Not completed | 18 | 20 | 16 |
Mean change in the total WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain subscale score for the target knee was compared to determine the clinical equivalence of Test Drug (Diclofenac sodium gel of 1% of Mylan Inc.) with the Reference Listed Drug (RLD) (Voltaren® Gel 1% of Novartis Consumer Health, Inc.) Measure Description: Western Ontario and McMaster Universities Osteoarthritis Index WOMAC pain subscale score (pain score = min 0 to max 20), was determined by the sum of subject's responses to five questions (S1-S5) using a 5-point Likert scale (i.e., 'none'=0; 'mild'=1, 'moderate'=2; 'severe'=3; 'extreme'=4). Higher values represent worse outcome. 'How much pain do you have' when 'Walking on a flat surface' (S1), 'Going up or down stairs' (S2), 'at night while in bed' (S3), 'Sitting or lying' (S4), 'Standing upright' (S5)\]. The timepoints considered for the primary outcomes include baseline and week 4.
| score on a scale | Diclofenac Sodium Gel | Voltaren® Gel |
|---|---|---|
| Mean Change in the Total WOMAC Pain Subscale Score | -4.3 ± 2.64 | -4.6 ± 2.64 |
Mean change in the total WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain subscale score for the target knee was compared to determine the superiority of the Test Drug and Reference Listed Drug (RLD) over placebo. Measure Description: Western Ontario and McMaster Universities Osteoarthritis Index WOMAC pain subscale score (pain score = min 0 to max 20), was determined by the sum of subject's responses to five questions (S1-S5) using a 5-point Likert scale (i.e., 'none'=0; 'mild'=1, 'moderate'=2; 'severe'=3; 'extreme'=4). Higher values represent worse outcome. 'How much pain do you have' when 'Walking on a flat surface' (S1), 'Going up or down stairs' (S2), 'at night while in bed' (S3), 'Sitting or lying' (S4), 'Standing upright' (S5)\]. The timepoints considered for the primary outcomes include baseline and week 4.
| score on a scale | Diclofenac Sodium Gel | Voltaren® Gel | Placebo Gel |
|---|---|---|---|
| Change From Baseline in WOMAC Pain Subscale Score | -4.2 ± 2.84 | -4.4 ± 2.74 | -3.2 ± 3.46 |
Collected over The reporting period for TEAEs started after the informed consent through day 28 after the last application of investigational product, a total of approximately 12 weeks.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Diclofenac Sodium Gel | 0/398 (0%) | 0/398 (0%) | 11/398 (2.8%) |
| Voltaren® Gel | 1/405 (0.2%) | 1/405 (0.2%) | 19/405 (4.7%) |
| Placebo Gel | 0/400 (0%) | 0/400 (0%) | 20/400 (5%) |
| Event | Diclofenac Sodium Gel | Voltaren® Gel | Placebo Gel |
|---|---|---|---|
| Completed SuicidePsychiatric disorders | 0/398 | 1/405 | 0/400 |
| Event | Diclofenac Sodium Gel | Voltaren® Gel | Placebo Gel |
|---|---|---|---|
| HeadacheNervous system disorders | 4/398 | 9/405 | 11/400 |
| PyrexiaGeneral disorders | 6/398 | 6/405 | 9/400 |
| EosinophiliaBlood and lymphatic system disorders | 1/398 | 4/405 | 0/400 |
| Age, Continuous(years) | Diclofenac Sodium Gel | Voltaren® Gel | Placebo Gel | Total |
|---|---|---|---|---|
| Mean | 53.3 ± 9.51 | 53.4 ± 9.40 | 53.6 ± 10.15 | 53.4 ± 9.68 |
| Sex: Female, Male(Participants) | Diclofenac Sodium Gel | Voltaren® Gel | Placebo Gel | Total |
|---|---|---|---|---|
| Female | 275 | 288 | 273 | 836 |
| Male | 131 | 121 | 132 | 384 |
| Race/Ethnicity, Customized(Participants) | Diclofenac Sodium Gel | Voltaren® Gel | Placebo Gel | Total |
|---|---|---|---|---|
| Asian/Not Hispanic or Latino | 406 | 409 | 405 | 1220 |
| Region of Enrollment(participants) | Diclofenac Sodium Gel | Voltaren® Gel | Placebo Gel | Total |
|---|---|---|---|---|
| India | 406 | 409 | 405 | 1220 |
| WOMAC Pain subscale score for target knee(units on a scale) | Diclofenac Sodium Gel | Voltaren® Gel | Placebo Gel | Total |
|---|---|---|---|---|
| Mean | 12.4 ± 2.15 | 12.5 ± 2.16 | 12.4 ± 2.05 | 12.4 ± 2.12 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2017 to primary completion in Dec 2017, 6 months.
Results were first posted in Apr 2021, 3 years 4 months after primary completion. A results delay was requested in Jul 2018.
Of 65 industry-sponsored phase 3 interventional studies under Osteoarthritis, Knee, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 27. This study's 6 months is below that.
Counting every sponsor, half of 101 studies reached it within 22 months; a quarter within 15 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Diclofenac Sodium Gel